Vildagliptin PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering a Vildagliptin range of 9 formulations in tablet form to distributors and franchise partners across India, with district-level monopoly rights on every SKU.

What is Vildagliptin?

Vildagliptin is an oral antidiabetic drug of the DPP-4 inhibitor (gliptin) class. It blocks dipeptidyl peptidase-4, the enzyme that rapidly breaks down the body's own incretin hormones GLP-1 and GIP. With the enzyme inhibited, those incretins persist for longer, and they in turn increase insulin secretion from pancreatic beta cells and suppress inappropriate glucagon release from alpha cells. Crucially, this action is glucose-dependent — it operates when blood sugar is high and stands down when it is not — which is why the risk of hypoglycaemia is low and body weight is largely unaffected. It is used in type 2 diabetes, typically alongside metformin, and is prescription-only. Compound and pharmacology data are available on PubChem.

Vildagliptin Formulations Available with Cafoli Lifecare

The Vildagliptin portfolio comprises 9 formulations in tablet form, including fixed-dose combination products. Composition, packing and net rate details are shared on enquiry.

Therapeutic Applications of Vildagliptin

• Type 2 diabetes mellitus as monotherapy where metformin is unsuitable
• Dual therapy with metformin, a sulfonylurea or an SGLT2 inhibitor
• Triple therapy in patients not controlled on two agents
• Add-on therapy in patients on insulin, at the physician's discretion

Prescribers are diabetologists, endocrinologists, general physicians, cardiologists and nephrologists. It has no role in type 1 diabetes or diabetic ketoacidosis.

Why Vildagliptin is a High-Potential Molecule for Distributors

Diabetes is the single largest chronic prescription market in India, and its most important commercial feature for a distributor is that almost nobody stays on one drug. Type 2 diabetes is a progressive disease: patients start on metformin, and within a few years most need a second agent added. Vildagliptin is one of the two or three molecules physicians most commonly reach for at that step, because its glucose-dependent action means it can be added to an elderly patient or an irregular eater without the hypoglycaemia risk a sulfonylurea would bring. Now that the molecule is off-patent, that clinical preference translates into an enormous fixed-dose combination market — and a 9-SKU range lets a partner cover the mono, dual and triple therapy steps of the same patient's journey from one catalogue. The therapy is lifelong and the refill is monthly, so every patient captured is an annuity, not a transaction.

Why Choose Cafoli Lifecare for Your Vildagliptin Franchise

• Monopoly rights — one partner per district, territory protected
• WHO-GMP certified manufacturing and DCGI-approved formulations
• Promotional inputs — visual aids, doctor sample packs, patient literature, reminder gifts and MR bags
• 1000+ franchise partners across India
• On-time despatch, transparent net rates and dedicated order support

References

1. PubChem — Vildagliptin compound record, National Library of Medicine
2. WHO — Diabetes fact sheet
3. PubMed — clinical literature on vildagliptin in type 2 diabetes